Tuesday, February 09, 2016 3:22:51 PM
If you want proof that company is committed to not do an R/S look at their actions.
By best estimate COWI revenue is 6 to 7 million per year and they have 2.7 million in convertible debt. Current OS is around 9 Billion. The 2.7 million would convert to between 55 and 77 Billion shares (I didn't bother to do the actual conversion math from the Q, but you can see it's an enormous amount of shares).
With only 7 million in revenue there is no way that a company would divert 1 to 2 million of that revenue to pay off CD and avoid conversion if they had any plan of RS. If they were thinking of doing another R/S they would not negotiate forbearance for the debt and start making cash payments, they would just raise the AS and let the conversions continue. So far they have announced agreements for almost 40% of the 2.7 million. I believe that they are in talks with other note holders and we will hear even more announcement in the near future. If they weren't they would have already been required to raise the A/S to accommodate potential conversions.
At any rate this the logic I'm using to justify my buy and hold at this time.
Recent COWI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/01/2023 09:20:45 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:47:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 12:30:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/22/2023 07:13:47 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:00:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 12:35:32 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 07/17/2023 02:06:52 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 06/28/2023 06:46:02 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM